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The scavenger receptor C-type lectin (SRCL) is an en-
dothelial receptor that is similar in organization to type A
scavenger receptors formodified lowdensity lipoproteins
but contains a C-type carbohydrate-recognition domain
(CRD). Fragments of the receptor consisting of the entire
extracellular domain and the CRD have been expressed
and characterized. The extracellular domain is a trimer
held together by collagen-like and coiled-coil domains ad-
jacent to the CRD. The amino acid sequence of the CRD is
very similar to theCRDof the asialoglycoprotein receptor
and other galactose-specific receptors, but SRCL binds
selectively to asialo-orosomucoid rather than generally to
asialoglycoproteins. Screening of a glycan array and fur-
ther quantitative binding studies indicate that this selec-
tivity results from high affinity binding to glycans bear-
ing the Lewisx trisaccharide. Thus, SRCL shares with the
dendritic cell receptor DC-SIGN the ability to bind the
Lewisx epitope. However, it does so in a fundamentally
different way, making a primary binding interactionwith
the galactose moiety of the glycan rather than the fucose
residue. SRCL shares with the asialoglycoprotein recep-
tor the ability to mediate endocytosis and degradation of
glycoprotein ligands. These studies suggest that SRCL
might be involved in selective clearance of specific desia-
lylated glycoproteins from circulation and/or interaction
of cells bearing Lewisx-type structures with the vascular
endothelium.
The scavenger receptor C-type lectin (SRCL)1 is also known
as collectin-placenta 1 (CL-P1). Although originally cloned
from liver and placenta, SRCL is expressed in many tissues (1,
2). The receptor is found in endothelial cells from human um-
bilical vein and artery as well as in vascular endothelial cells of
the heart, suggesting that it may be widely distributed in
endothelia. The SRCL polypeptide contains an N-terminal in-
tracellular domain, transmembrane anchor, and the extended
extracellular domain (Fig. 1). The extracellular portion of the
receptor is composed of a neck that contains coiled-coil and
collagen-like regions and a C-terminal carbohydrate-recogni-
tion domain (CRD).
The binding properties of SRCL have only been partially
characterized. Binding to oxidized low density lipoprotein par-
ticles has been demonstrated and, by analogy to the type A
scavenger receptors, this activity has been attributed to the
collagen-like domain (1). Binding to Gram-negative bacteria
has also been associated with the collagen-like domain, because
a variant form of the protein lacking CRDs still shows binding
activity for bacteria when expressed in Chinese hamster ovary
cells (2). Although the cytoplasmic domain of SRCL contains a
potential endocytosis signal motif, conflicting data have been
presented regarding the uptake of particulate ligands into cells
(1, 2).
C-type CRDs fall broadly into two subgroups, those that bind
galactose and related ligands and those that bind mannose,
N-acetylglucosamine, and fucose. Mutagenesis of galactose-
binding C-type CRDs, combined with studies in which the
specificity of a mannose-binding CRD was converted to galac-
tose binding, have led to the identification of a small set of
residues that are essential for high affinity binding to galactose
(3, 4). Examination of the sequence of SRCL reveals that all of
these key residues are present.2 Thus, SRCL differs from DC-
SIGN, the macrophage mannose receptor, serum mannose-
binding protein, and other C-type lectins known to have roles in
pathogen recognition, all of which fall into the second sub-
group. Semiquantitative binding studies using cells expressing
SRCL suggest that the receptor does bind sugar-containing
ligands, with some preference for N-acetylgalactosamine (5).
The overall organization of SRCL shares features of both the
type A scavenger receptors for modified low density lipoprotein
and the collectins, which are soluble C-type lectins involved in
pathogen recognition. The arrangement of domains in SRCL is
most like the arrangement of the type A scavenger receptors,
with the CRDs replacing cysteine-rich domains that are not
related in sequence (6). Sequence comparisons reveal sequence
similarities between the collagen-like and coiled-coil domains
of SRCL and all three of the type A scavenger receptors, with
particularly strong similarity to SR-A 3 (Fig. 1) (7). Although
the collagen-like and coiled-coil domains would have similar
elongated conformations in SRCL and the collectins, sequence
comparisons provide no evidence for homology between SRCL
and the collectins, and the domains are actually arranged in
reverse order in the polypeptides. In addition, comparison of
the CRD of SRCL with other C-type lectins shows that, in
evolutionary terms, this domain falls within the family of type
II transmembrane receptors that includes the asialoglycopro-
tein receptor, rather than forming part of the collectin cluster.
Thus, it seems likely that the presence of similar domains in
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SRCL and the collectins represents independent gene shuffling
events that have converged on a similar set of protein struc-
tural elements.
To assess the biological functions of SRCL, both the sugar-
binding characteristics and intracellular trafficking properties
of the receptor need to be better defined. To this end, the
results of this study demonstrated that the CRD of SRCL binds
with unusually high selectivity to glycans containing the
Lewisx epitope, that the CRDs are clustered in a trimer, and
that the receptor is able to direct uptake and degradation of
glycoprotein ligands.
EXPERIMENTAL PROCEDURES
Materials—Oligosaccharides and LNFP III-BSA were purchased
from Dextra Ltd. (Reading, UK). Galactose-BSA was obtained from E-Y
Laboratories (San Mateo, CA). Radioisotopes were from Amersham
Biosciences. Rabbit polyclonal antibodies to the CRD from SRCL were
generated by Eurogentec (Seraing, Belgium) following their standard
protocol using 2 mg of bacterially expressed protein as antigen.
Cloning of SRCL cDNA—cDNA encoding human SRCL was ampli-
fied from human placental cDNA (Clontech) in two sections using the
following pairs of primers: N-terminal section forward, 5-AACCCACG-
GTCACGGTCACCATGAAAGACGACTTCGCAG-3; N-terminal sec-
tion reverse, 5-TTGAGCTGACCATGCTTGGAGTCTACTAGCTTC-3;
C-terminal section forward, 5-AAGTGGTCATCATGAACCTCAACA-
ACCTGAACCTG-3; C-terminal section reverse, 5-TTGCGGCCGCT-
TATAATGCAGATGACAGTACTGTCTCCCTGTC-3. Following dena-
turation at 95 °C for 1 min, 40 cycles of 95 °C for 30 s, and 68 °C for 1
min were carried out. PCR products were cloned into the vector pCRII-
TOPO using the TOPO cloning kit (Invitrogen) and sequenced using an
Applied Biosystems Prism 310 genetic analyzer. Segments of the
cDNAs that were free of reverse transcription errors were combined
using convenient restriction sites.
Expression of the CRD fromSRCL in Bacteria—The region of the cDNA
coding for the CRD only (from residue 603 to the C terminus) was ampli-
fied using the following primers: forward primer, 5-AAGGCCGG-
CCGAGGACAATAGCTGCCCGCCTCACTGGAAG-3; reverse primer, 5-
TTGCGGCCGCTTATAATGCAGATGACAGTACTGTCTCCCTGTC-3.
PCR products were digested at the FseI and NotI sites in the primers and
inserted into a modified pINIIIompA2 expression vector containing re-
striction sites for FseI and NotI downstream of the ompA signal sequence
(8). The correct reading frame was generated by digesting the vector with
FseI, followed by trimming of the 3 extension with T4 polymerase and
religation. The integrity of the final expression plasmid was verified by
DNA sequencing. Luria-Bertani medium (1 liter), containing 50 g/ml
ampicillin, was inoculated with 30 ml of an overnight culture of Esche-
richia coli strain JA221 transformed with the expression plasmid. The
culture was grown by shaking at 25–30 °C to an A550 of 0.8, and isopro-
pyl--D-thiogalactoside and CaCl2 were added to final concentrations of 50
M and 100 mM, respectively. After growth, for a further 18 h at 25–30 °C,
the cells were harvested by centrifugation at 4,000 rpm for 15 min in a
Beckman JS-4.2 rotor. Bacterial pellets were resuspended in cold 10 mM
Tris-Cl, pH 7.8, followed by centrifugation at 12,000 rpm for 15 min at
4 °C in a Beckman JA14 rotor. Bacteria were sonicated in 30 ml of 20 mM
Tris-Cl, pH 7.8, 0.5 M NaCl, 20 mM CaCl2 (loading buffer). Lysed bacteria
were centrifuged at 10,000 g for 15 min, and the supernatant was
recentrifuged at 100,000 g for 1 h at 4 °C. The supernatant was passed
over a 10-ml column of galactose-Sepharose (9) equilibrated in loading
buffer. The column was washed with 10 2 ml of loading buffer and
eluted with 10 2ml of elution buffer (20 mM Tris-Cl, pH 7.8, 0.5 M NaCl,
2 mM EDTA). Fractions were analyzed by SDS-polyacrylamide gel elec-
trophoresis. The CRD was identified by N-terminal sequencing on a
Beckman LF3000 protein sequencer following transfer to polyvinylidene
difluoride membranes (10).
Expression of the Extracellular Domain of SRCL in Chinese Hamster
Ovary Cells—DNA coding for the extracellular domain of SRCL, with-
out the cytoplasmic tail and the transmembrane region, was produced
by amplifying the region coding for the N-terminal section of the protein
using the forward primer 5-AAAGTTGTAGAGAAATGGACAATGT-
CACAGGTGCC-3 with the reverse primer described above and com-
bining this section with the region coding for the C-terminal section
amplified as above. The resulting DNA, coding for the entire extracel-
lular domain of SRCL (starting at residue 60), was fused to codons
specifying the dog preproinsulin signal sequence. The preproinsulin
signal sequence has previously been shown to direct efficient secretion
of other truncated receptors (11, 12). The modified cDNA was inserted
into the vector pED between the XbaI and EcoRI sites following the
region encoding the adenovirus major late promoter and preceding the
region encoding the dihydrofolate reductase gene (13). The resulting
plasmid was transfected into DXB11 Chinese hamster ovary cells
(which are deficient in dihydrofolate reductase) using the calcium phos-
phate method (14). Transfectants were selected by growth in minimal
essential  medium without nucleosides and supplemented with 10%
(v/v) dialyzed fetal calf serum. Amplification of protein expression was
achieved by passaging cells into medium containing increasing concen-
trations (up to 0.5 M) of methotrexate over several weeks. For protein
production, cells were grown in medium containing 0.5 M methotrex-
ate. Once the cells reached confluence, the medium was changed and
batches of medium were harvested every 2 days for 8 days. Tris-Cl, pH
7.8, CaCl2, and NaCl were added to the medium to give final concen-
trations of 20 and 20 mM and 0.5 M, respectively. Following centrifuga-
tion at 10,000 rpm in a Beckman JA14 rotor for 15 min, the medium
was loaded onto a 10-ml column of galactose-Sepharose equilibrated in
loading buffer. The column was washed with loading buffer before
elution with elution buffer.
Expression of Full-length SRCL in Fibroblasts—DNA coding for full-
length SRCL was inserted into the retroviral expression vector pVcos (15)
at the EcoRI site. The neomycin resistance gene, under the control of the
herpes virus thymidine kinase promoter, was inserted into the resulting
vector at the unique ClaI site (16). The final plasmid was transfected into
Cre packaging cells to produce a pseudovirus that was used to infect
Rat-6 fibroblasts, and fibroblast lines stably expressing SRCL were se-
lected using G418 (17). Cells were harvested by scraping, suspended in
10 volumes of 125 mM NaCl, 10 mM Tris-Cl, pH 7.5, and 0.5% Triton
X-100, sonicated briefly, incubated 1 h at 4 °C, and spun for 2 min at
18,000 g. The supernatant was analyzed by SDS-polyacrylamide gel
electrophoresis on a 12% gel, which was blotted onto nitrocellulose and
probed with antibodies raised against the CRD (18).
Analytical Ultracentrifugation—Equilibrium sedimentation analysis
was carried out in a Beckman Optima XL-A analytical Ultracentrifuge
equipped with absorbance optics using an An60Ti rotor at 20 °C. Pro-
teins were dialyzed extensively against 10 mM Tris-Cl, pH 7.8, 100 mM
NaCl, 10 mM CaCl2. The extracellular domain of SRCL was analyzed at
5,000 and 8,000 rpm. For the CRD, rotor speeds of 10,000 and 21,000
rpm were used. Equilibrium distributions from three different loading
concentrations (0.5, 0.25, and 0.125 mg/ml for the extracellular domain
and 0.2, 0.1, and 0.05 mg/ml for the CRD) were analyzed simulta-
neously using the Nonlin curve fit program supplied with the instru-
ment. Partial specific volumes for the SRCL fragments were deter-
mined from their amino acid composition and estimates of the extent of
glycosylation (19).
Labeling of the Extracellular Domain of SRCL—For radio-iodination,
the extracellular domain of SRCL, 100 g of protein in 1.5 ml, was
dialyzed against 150 mM NaCl, 25 mM HEPES, pH 7.8, 5 mM CaCl2 and
reacted with 50 Ci of 125I-Bolton-Hunter reagent for 15 min at room
temperature (20). Labeled protein was repurified by affinity chroma-
tography on galactose-Sepharose. For fluorescent labeling, 250 g of
protein was dialyzed against water, lyophilized, dissolved in 0.5 ml of
0.5 M NaCl, 20 mM Na-bicine, 5 mM CaCl2, and reacted with 75 g
of fluorescein isothiocyanate that was dissolved at 1 mg/ml in dimethyl
sulfoxide and added as five aliquots of 15 l, followed by reaction
overnight at 4 °C. EDTA was added to a concentration of 10 mM, and the
labeled protein was repurified by gel filtration on a 10  300-mm Su-
perdex 200 column (Amersham Biosciences) eluted with 0.1 M NaCl, 10
mM Tris-Cl, pH 7.8, 2.5 mM EDTA at a flow rate of 0.5 ml/min.
Probing of Ligands—Glycoproteins were resolved on a 17.5% SDS-
polyacrylamide gel and transferred to nitrocellulose. All of the glyco-
proteins were of bovine origin, except orosomucoid, which was from
human serum. The blot was blocked at room temperature for 1 h with
2% bovine hemoglobin in wash buffer (125 mM NaCl, 25 mM Tris-Cl, pH
7.8, and 25 mM CaCl2) and reacted for 1 h with the radio-iodinated
extracellular domain of SRCL in the same solution at a concentration of
1 g/ml. The blot was washed four times for 5 min each with cold wash
buffer, and radioactivity was detected using a phosphorimaging device
from Molecular Dynamics. Neoglycolipids, prepared by coupling oligo-
saccharides to phosphatidylethanolamine dipalmitate, were resolved by
thin layer chromatography and fixed with isobutylmethacrylate (21).
The chromatograms were then blocked and probed as for the glycopro-
tein blots. Fluorescein-labeled extracellular domain was used to probe
the glycan array following the standard procedure of Core H of the
Consortium for Functional Glycomics.3
3 www.functionalglycomics.org.
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Solid Phase Binding Assays—Polystyrene wells were coated over-
night with either CRD or the extracellular domain of SRCL at a con-
centration of 50 g/ml in loading buffer. Neoglycoprotein reporter
ligands were created by iodination (22). Binding competition experi-
ments and determination of the pH dependence of binding were per-
formed as previously described (17). Binding data were fitted using
SigmaPlot software (Jandel Scientific).
Molecular Modeling—The crystal structure of the galactose-binding
derivative of mannose-binding protein with bound galactose was used
as a starting point (23). The structure of the Lewisx trisaccharide
abstracted from the crystal structures of this ligand bound to DC-SIGN
was used to model the ligand (24), although similar results were ob-
tained using coordinates derived from the crystal structure of sialyl-
Lewisx bound to E-selectin and from the NMR structure of the free
oligosaccharide. The galactose moiety of Lewisx was manually super-
imposed onto the galactose in the mannose-binding protein structure
using Insight II modeling software.
Endocytosis Experiments—Analysis of uptake and degradation of
125I-Gal-BSA or 125I-LNFP III-BSA by fibroblasts expressing SRCL was
performed as described previously (25).
RESULTS
Expression and Characterization of the SRCL Extracellular
Domains—To initiate a study of the ligand-binding properties
of SRCL, the C-terminal CRD was expressed in bacteria,
whereas the entire extracellular domain was expressed in Chi-
nese hamster ovary cells (Fig. 1). In the latter case, the insulin
signal sequence was used to direct the protein to the endoplas-
mic reticulum so that it could be modified by hydroxylation and
glycosylation before secretion into the medium. Both fragments
of SRCL could be purified by affinity chromatography on ga-
lactose-Sepharose (Fig. 2). The CRD, on its own, binds weakly
and washes off the affinity column even in the presence of
Ca2. The extracellular domain binds more effectively, and
columns of sufficient capacity can be washed with Ca2-
containing buffer and eluted with EDTA. The extracellular
domain fragment migrated as a broad band on SDS-polyacryl-
amide gels, suggesting that there is considerable heterogeneity
in post-translational modification. The apparent molecular
weight of 110–115 kDa deduced from the gels was consistent
with the predicted presence of up to 13 N-linked glycans, 8
O-linked glycans, and mono- or disaccharide residues attached
to hydroxylysine residues, all appended to a core polypeptide
of 75 kDa.
Weak binding to highly substituted sugar resins is often
characteristic of monomeric forms of C-type lectins. Therefore,
the oligomeric states of the fragments were analyzed by equi-
librium analytical ultracentrifugation (Fig. 3). The results
demonstrated that the CRD is monomeric, but the entire ex-
tracellular domain formed a stable trimer. This result is con-
sistent with the presence of the collagen-like domain, which
would be expected to direct trimerization. In addition, the
sequence of the N-terminal portion of the extracellular domain
was predicted to form a 3-stranded coiled coil of -helices,
which would further stabilize the trimer. The relatively weak
binding of both the CRD and the extracellular domain to ga-
lactose-Sepharose contrasts with other galactose-binding C-
type lectins, such as the asialoglycoprotein receptor and the
Kupffer cell receptor. Both monomeric and trimeric fragments
of these receptors bind tightly to this resin and can only be
eluted with EDTA, indicating that these receptors have inher-
ently higher affinity for galactose. These results suggest that
galactose on its own is not an optimal ligand for SRCL.
Binding of SRCL to Lewisx and Related Structures—An ini-
tial screening for higher affinity ligands was undertaken by
testing the binding of SRCL to a selection of glycoproteins. The
glycoproteins were resolved by SDS-polyacrylamide gel electro-
phoresis, blotted onto nitrocellulose, and probed with the ra-
diolabeled extracellular domain of SRCL (Fig. 4). Strong bind-
ing to asialo-orosomucoid is evident, but no binding to other
desialylated glycoproteins was detected. Binding to glycopro-
teins bearing sialylated complex, high mannose, or sulfated
N-linked glycans was also not detected.
There are two relatively unusual features to the N-linked
FIG. 1. Domain organization of SRCL and sequence compari-
sons with type A scavenger receptors. SR-A 1 and 2 are products of
alternatively spliced mRNAs from a single gene, whereas SR-A 3 is the
product of a distinct gene. The sequence comparisons suggest that
SRCL is most similar to SR-A 3, as it has collagen-like and coiled-coil
domains of exactly the same lengths. In SR-A 1 and 2, both regions are
truncated.
FIG. 2. Gel electrophoresis of fractions from affinity chroma-
tography of fragments of SRCL on galactose-Sepharose. Frac-
tions from washing in the presence of Ca2 (W) and elution with EDTA
(E) are shown. Gels were stained with Coomassie Blue.
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glycans on asialo-orosomucoid. First, many of the glycans have
highly branched tri- and tetra-antennary structures. Second,
many of these branches bear outer-arm fucose residues (26).
The contribution of these two features to the binding of SRCL
to asialo-orosomucoid was assessed by testing the binding to
highly branched glycans lacking fucose residues and glycans
bearing single terminal fucose residues. The glycans were pre-
sented as neoglycolipids resolved by thin layer chromatography
(Fig. 5). The radiolabeled extracellular domain of SRCL binds
to the Lewisx- and Lewisa-containing ligands but not to the
branched, unfucosylated oligosaccharides. Thus, SRCL shows
selectivity for glycans bearing both terminal galactose and
fucose residues.
A broader view of the binding selectivity of SRCL was ob-
tained by probing a glycan array with fluorescently labeled
extracellular domain. The array consists of over 150 different
biotinylated oligosaccharides presented on streptavidin immo-
bilized in polystyrene wells. The results reveal a striking se-
lectivity for glycans containing terminal Lewisx trisaccharides,
with no binding to sulfated or sialylated forms of these glycans
(Fig. 6). Weaker binding was also observed for the isomeric
Lewisa trisaccharide and to Lewisx, in which the galactose is
substituted by N-acetylgalactosamine. In addition, very weak
binding to blood group H substances was detected. The high
degree of selectivity of SRCL is relatively unusual among C-
type lectins.
Selectivity for Lewisx and Mechanism of Binding—Previous
studies with the dendritic cell receptor DC-SIGN have revealed
that this receptor, similar to SRCL, binds Lewisx and other
glycans that bear terminal fucose and galactose residues, al-
though it binds a broader range of such glycans. The primary
binding site in the C-type CRD of DC-SIGN binds to the fucose
moiety (24), whereas the primary binding site in SRCL has the
FIG. 3. Sedimentation equilibrium
analytical ultracentrifugation of
SRCL fragments. Data for three differ-
ent loading concentrations, shown as
symbols, were fitted globally, with the fit-
ted curve shown as continuous lines. The
deduced Mr of the CRD is 17,000 com-
pared with theMr of the CRD polypeptide
calculated from the amino acid sequence,
which is 16,441. The measured Mr of the
extracellular domain is 317,000, which
falls in the range of values calculated for a
trimer with various possible degrees of
glycosylation (313,000–322,000). Similar
results were obtained at two different
speeds for each sample. Results for 21,000
rpm for the CRD and 5,000 rpm for the
extracellular domain are shown.
FIG. 4. Binding of 125I-SRCL to glycoproteins. Aliquots of 2 g
of each glycoprotein were resolved by SDS-polyacrylamide gel electro-
phoresis on a 17.5% gel. Portions of the gel were stained with Coomassie
Blue and blotted onto nitrocellulose for probing with 125I-SRCL. SBA,
soybean agglutinin. RNase, ribonuclease. Samples in the first lane
contain high mannose and hybrid glycans. Thyrotropin in the final lane
contains sulfated glycans. Orosomucoid, fetuin, transferrin, and fibrin-
ogen bear sialylated complex glycans.
FIG. 5. Binding of 125I-SRCL to neoglycolipids. A, chromatogram
was developed with CHCl3/methanol/H2O 105:100:28. B, chromatogram
was developed with CHCl3/methanol/H2O 11:9:2. Parallel chromato-
grams were stained with orcinol or fixed and probed with 125I-SRCL.
LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose. The boxes indicate
Lewisx and Lewisa trisaccharide structures.
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hallmarks of a galactose-binding site. To clarify the nature of
the primary monosaccharide-binding site, studies comparing
the affinities of galactose, fucose, and Lewisx trisaccharide
were conducted (Fig. 7). The results, summarized in Table I,
confirm that the affinity of SRCL for Lewisx trisaccharide is
much higher than the affinity for galactose. The affinity for
fucose is roughly 4-fold lower than the affinity for galactose,
suggesting that galactose is the primary site ligand. Compari-
son of -methyl galactoside and -methyl fucoside binding
shows an even stronger preference for the galactose moiety,
probably because the presence of the methyl group eliminates
artifactual binding through the 1-hydroxyl group (27).
The availability of a crystal structure for a galactose-binding
variant of the CRD from rat serum mannose-binding protein
made it possible to model the binding site of SRCL. The con-
formation of the Lewisx trisaccharide was derived from one of
the several crystal structures that contain this oligosaccharide
as part of a larger structure, and the galactose moiety was
superimposed on the galactose residue in the CRD structure.
Galactose occupies a primary binding site that involves coordi-
nation with Ca2 and hydrophobic packing with a tryptophan
residue (Fig. 8). The model shows that the fucose residue in the
Lewisx structure can be accommodated in the binding site with
no steric clashes. The structure also suggests that the fucose
might interact with the short segment-designated loop 5, con-
sisting of the sequence Lys-Ala-Gly at residues 691–693. Mu-
tants in which the sequence of the loop was modified to Arg-
Pro-Gly, as found in the asialoglycoprotein receptor, or to Ala-
Ala-Gly, to eliminate most potential side chain interactions,
failed to change the affinity for Lewisx compared with galactose
(data not shown). These results suggest that interactions
with loop 5 might be with backbone atoms rather than the
side chains.
A weak binding interaction with the blood group H sub-
stances was also detected in the glycan array. Because these
oligosaccharides do not contain terminal galactose residues, it
was interesting to consider how they might be accommodated
in the binding site. The fucose residue in these structures is
attached to the 2 position of galactose, so the arrangement of
coordination ligands with the 3- and 4-hydroxyl groups need
not be perturbed. As no crystal structure with the H-type
glycans has been reported, it is not possible to develop a de-
tailed model of where the fucose residue is located. However,
modeling of a fucose residue in linkage to the 2-hydroxyl group
of galactose suggests that it can be accommodated and that it
might make energetically favorable contacts with loop 5 or
other residues on the surface of the CRD. Thus, the binding and
modeling results provide a consistent picture of galactose- and
fucose-containing oligosaccharides interacting with SRCL
through a primary galactose-binding site and secondary con-
tacts with fucose.
Endocytic Activity of SRCL—Although SRCL binds selec-
tively to Lewisx-type structures, its binding activity overlaps
with the binding activity of the asialoglycoprotein receptor. The
presence of SRCL on endothelial cells suggests that it might
interact with a subset of circulating glycoproteins from which
terminal sialic acid has been removed. It was, therefore, of
interest to examine the ability of SRCL to mediate uptake of
such glycoproteins.
The cytoplasmic domain of SRCL contains the sequence Tyr-
Lys-Arg-Phe, which is a potential target for binding of adapter
proteins that direct receptors to clathrin-coated pits for endo-
cytosis (29). Studies with other receptors suggest that, in ad-
FIG. 7. Binding competition assays for SRCL. Competition as-
says for binding to SRCL-coated wells were performed using 125I-LNFP
III-BSA as reporter ligand. Assays were performed two or three times in
duplicate, and representative results are shown.
TABLE I
Summary of binding competition assays for SRCL
The CRD of SRCL was immobilized on polystyrene wells and probed
with 125I-labeled LNFP III-BSA in the presence of competing sugars.
Similar results were obtained using the trimeric extracellular domain
and when 125I-Gal-BSA was used as the reporter ligand. The KI repre-
sents the concentration of free sugar needed to achieve 50% inhibition
of reporter ligand binding. Assays were performed at least three times
in duplicate for each competing sugar, except for Lewisx, which was
tested twice in duplicate. Values reported are means  S.D.
Competing sugar KI KI,sugar/KI,galactose
mM
Galactose 7.5  2.0 1
N-Acetylgalactosamine 1.9  0.5 0.28  0.05
-Methyl galactoside 10.1  2.6 1.5  0.3
Fucose 24.5  4.3 3.8  0.4
-Methyl fucoside 70  19 11.5  2.1
Lewisx 0.149  0.8 0.014  0.006
FIG. 6. Binding of fluorescein-la-
beled SRCL to glycan array. Biotin
glycosides were immobilized in streptavi-
din-coated wells. Binding and washing
were conducted in the presence of 150 mM
NaCl, 25 mM Tris-Cl, pH 7.5, and 2 mM
CaCl2. The level of fluorescence was nor-
malized to glycan 25 (Lewisx).
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dition to such sorting signals, clearance activity requires the
receptor be capable of ligand release at endosomal pH. There-
fore, the ability of SRCL to release ligand in a pH-dependent
manner was examined (Fig. 9). The results demonstrate that
binding of carbohydrate ligands to SRCL is extremely depend-
ent on pH, with a midpoint for release of ligand at a physiolog-
ical Ca2 concentration of approximately pH 6.5. This value is
very similar to that observed for the asialoglycoprotein recep-
tor, DC-SIGN, and other C-type lectins that function in endo-
cytosis (24, 30). The steepness of the curve suggests that the
transition from a binding to a nonbinding conformation in-
volves titration of multiple groups in the CRD.
Based on these results, the endocytic activity of SRCL was
investigated by expressing the full-length receptor in rat
fibroblasts. Western blotting of cell extracts with antibodies
raised to the CRD of SRCL was used to confirm that the
protein was expressed, and endocytic activity was measured
using 125I-LNFP III-BSASY as a test ligand. Following an
initial interaction with the cells, the ligand is gradually de-
graded and released back into the medium in acid-soluble
form. The turnover calculated from an estimate of the num-
ber of receptors/cell is similar to that for other endocytic
receptors in the C-type lectin family expressed in the same
cell background. Similar results were obtained with 125I-Gal-
BSA. These results confirm that the receptor can mediate
endocytosis and might be able to clear a selected set of asia-
loglycoproteins, including asialo-orosomucoid.
DISCUSSION
Similar to SRCL, serum mannose-binding protein and other
collectins contain C-type CRDs, collagen-like domains and re-
gions consisting of coiled coils of  helices (31). Because of the
well established roles of several of the collectins in innate
immunity, a similar role has been suggested for SRCL (1, 2).
The results presented here, as well as the evolutionary consid-
erations discussed in the Introduction, suggest that other pos-
sible functions for SRCL need to be considered.
The fact that bacteria and yeast can interact with SRCL is
consistent with a role in innate immunity (1, 2). However, it is
important to note that SRCL is found on endothelial cells
rather than cells such as macrophages or dendritic cells that
are usually associated with the innate immune response. In
addition, the way that SRCL interacts with microbes is very
different from the way that the collectins bind to them. The
CRDs of the collectins fall into the subcategory of C-type lectins
that bind to mannose, GlcNAc, and related sugars (3). They
bind weakly to individual sugars and achieve selective binding
to the surfaces of bacteria and fungi by interacting with repeat-
ing arrays of sugars in the walls of these micro-organisms (32).
The data on binding selectivity presented here indicate that the
CRD of SRCL falls into the other subcategory of C-type CRDs,
which bind galactose and related sugars in the primary binding
site. This specificity is not typical of pathogen-binding mole-
cules. Indeed, a truncated form of SRCL lacking the CRD
seems to retain the ability to bind micro-organisms, leading to
the suggestion that the binding site lies on the collagen-like
domain (2). In contrast, the collagen-like domain of serum
mannose-binding protein interacts with serine proteases that
activate complement (33). Thus, SRCL differs from the collec-
tins both in arrangement of domains and the functions of
these domains.
The preferred ligands for SRCL have adjacent terminal ga-
lactose and fucose residues. Thus, SRCL shares with DC-SIGN
the ability to bind Lewisx-containing oligosaccharides (24).
However, DC-SIGN binds a much broader range of fucose-
FIG. 8. Model of SRCL-binding site. Crystal structures of Lewisx
and a galactose-binding mutant of mannose-binding protein were com-
bined to model SRCL. The primary binding site accommodates galac-
tose through hydrogen bonding (dashed black lines), coordination bonds
to Ca2 (solid red lines), and hydrophobic packing of the B face against
the side chain of a tryptophan residue (green curves). Possible secondary
interactions of fucose would involve loop 5. This figure was generated
using Molscript (28).
FIG. 9. pH dependence of ligand binding to SRCL. The curve
was fitted to a binding equation in which both the pH of half-maximal
binding and the order of the reaction were allowed to vary (30). Based
on three separate assays, half-maximal binding is observed at pH
6.54  0.04, n  3.7  0.7.
FIG. 10.Uptake and degradation of 125I-LNFP III-BSA by fibro-
blasts expressing SRCL. Cells were preincubated for 30 min at 4 °C
with ligand at a concentration of 2 g/ml. Following incubation at 37 °C
for the times indicated, the cells were returned to 4 °C, the incubation
medium collected, and the cells were washed three times with cold
medium not containing ligand. Cell-associated radioactivity and acid-
soluble degradation products released back into the medium were
quantified.
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containing ligands, and the relative roles of fucose and galac-
tose in the binding interaction are reversed. The different lo-
calizations of SRCL and DC-SIGN suggest that, despite their
overlapping ability to bind the Lewisx structure, they would
probably target different glycoconjugate ligands.
The highly specific binding of SRCL to the Lewisx trisaccha-
ride suggests other possible roles for this receptor in the selec-
tive clearance of specific desialylated glycoproteins from circu-
lation or selective interaction of cells bearing Lewisx-type
structures with the vascular endothelium. These roles would be
more analogous to the functions of the asialoglycoprotein re-
ceptor (34) and the selectin cell adhesion molecules (35). Sim-
ilar to the hepatic asialoglycoprotein receptor, SRCL has the
ability to bind asialo-orosomucoid. Differences in the number of
receptors may explain why the liver receptor normally provides
the predominant route for clearance of this glycoprotein from
circulation. SRCL might provide an alternative mechanism for
clearance of some asialo-glycoprotein in asialoglycoprotein re-
ceptor-deficient mice (36, 37), although most asialoglycopro-
teins (which lack outer arm fucose residues) would not be taken
up by this receptor.
The distribution of SRCL on vascular endothelial cells sug-
gests parallels with the selectins, which bind to elaborated
versions of the Lewisx trisaccharide, bearing sialic acid and
sulfate groups (35). The restricted binding to a specific glycan
structure suggests possible roles in cell adhesion analogous to
the leukocyte-endothelial interactions mediated by the selec-
tins. E- and P-selectin are selectively expressed at sites of
inflammation, whereas SRCL seems to be constitutively ex-
pressed on a wide variety of endothelial cells, although possible
modulation of SRCL expression remains to be investigated.
Knowledge of the glycan-binding selectivity of SRCL will also
allow further study of possible glycoprotein and cellular target
ligands.
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